-
公开(公告)号：US20180222868A1
公开(公告)日：2018-08-09
申请号：US15580054
申请日：2016-06-07
Applicant: UCB Biopharma SPRL
Inventor： Prafulkumar Tulshibhai Chovatia , Martin Clive Hutchings , Boris Kroeplien , James Thomas Reuberson
IPC: C07D231/56 , A61K31/416 , C07D403/04 , A61K31/506 , C07D403/14 , C07D413/14
CPC classification number: C07D231/56 , A61K31/416 , A61K31/506 , C07D403/04 , C07D403/14 , C07D413/14
Abstract: A series of substituted indazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US20150152065A1
公开(公告)日：2015-06-04
申请号：US14406848
申请日：2013-06-11
Applicant: UCB Biopharma SPRL
Inventor： Daniel Christopher Brookings , Mark Daniel Calmiano , Ellen Olivia Gallimore , Helen Tracey Horsley , Martin Clive Hutchings , James Andrew Johnson , Boris Kroeplien , Fabien Claude Lecomte , Martin Alexander Lowe , Timothy John Norman , John Robert Porter , Joanna Rachel Quincey , James Thomas Reuberson , Matthew Duncan Selby , Michael Alan Shaw , Zhaoning Zhu , Anne Marie Foley
IPC: C07D235/12 , C07D401/04 , A61K31/4439 , A61K31/454 , C07D405/06 , A61K31/4192 , C07D403/04 , A61K31/4709 , A61K31/4725 , A61K31/444 , C07D401/14 , A61K31/5377 , A61K31/541 , A61K31/551 , C07D491/107 , A61K31/506 , A61K31/4184
CPC classification number: C07D235/12 , A61K31/4184 , A61K31/4192 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4709 , A61K31/4725 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/551 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/06 , C07D491/107
Abstract: A series of benzimidazole derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Abstract translation: 因此，作为人TNFα活性的有效调节剂的一系列苯并咪唑衍生物有益于治疗和/或预防各种人类疾病，包括自身免疫和炎性疾病; 神经和神经退行性疾病; 疼痛和伤害性疾病; 心血管疾病; 代谢紊乱 眼部疾病; 和肿瘤疾病。
-
公开(公告)号：US20180298009A1
公开(公告)日：2018-10-18
申请号：US15762670
申请日：2016-09-28
Inventor： Daniel James Ford , Helen Tracey Horsley , James Thomas Reuberson
IPC: C07D487/04 , C07D498/04
Abstract: A series of substituted pyrazolo[1,5-a]pyrimidine and pyrazolo[1,5-a][1,3,5]-triazine derivatives of formula (I), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
-
公开(公告)号：US09815797B2
公开(公告)日：2017-11-14
申请号：US15101283
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
Inventor： Rikki Peter Alexander , Gregory Foulkes , Martin Clive Hutchings , Victoria Elizabeth Jackson , Boris Kroeplien , James Thomas Reuberson , Sarah Margaret Rook , Zhaoning Zhu
IPC: C07D239/74 , A61K31/47 , A61K31/472 , A61K31/498 , A61K31/506 , A61K31/517 , C07D215/14 , C07D237/28 , A61K31/502 , C07D215/06 , C07D237/32 , C07D241/44 , A61K45/06 , C07D217/16 , C07D241/42 , C07D403/04
CPC classification number: C07D239/74 , A61K31/47 , A61K31/472 , A61K31/498 , A61K31/502 , A61K31/506 , A61K31/517 , A61K45/06 , C07D215/06 , C07D215/14 , C07D217/16 , C07D237/28 , C07D237/32 , C07D241/42 , C07D241/44 , C07D403/04 , A61K2300/00
Abstract: A series of substituted heteroaromatic compounds containing two fused six-membered rings, tivity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US20170129905A1
公开(公告)日：2017-05-11
申请号：US15318422
申请日：2015-06-11
Inventor： Daniel James Ford , Qiuya Huang , Judi Charlotte Neuss , James Thomas Reuberson , Bart Vanderhoydonck
IPC: C07D498/04 , C07D487/04 , C07D495/04
CPC classification number: C07D498/04 , A61K31/519 , C07D487/04 , C07D495/04
Abstract: A series of fused bicyclic heteroaromatic derivatives of formula (IA) or (IB), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
-
Patent Agency Ranking
公开(公告)号：US20150203486A1
公开(公告)日：2015-07-23
申请号：US14414287
申请日：2013-07-05
Applicant: UCB Biopharma SPRL
Inventor： Jonathan Mark Bentley , Daniel Christopher Brookings , Julien Alistair Brown , Thomas Paul Cain , Praful Tulshi Chovatia , Anne Marie Foley , Ellen Olivia Gallimore , Laura Jane Gleave , Alexander Heifetz , Helen Tracey Horsley , Martin Clive Hutchings , Victoria Elizabeth Jackson , James Andrew Johnson , Craig Johnstone , Boris Kroeplien , Fabien Claude Lecomte , Deborah Leigh , Martin Alexander Lowe , James Madden , John Robert Porter , Joanna Rachel Quincey , Laura Claire Reed , James Thomas Reuberson , Anthony John Richardson , Sarah Emily Richardson , Matthew Duncan Selby , Michael Alan Shaw , Zhaoning Zhu
IPC: C07D471/04 , A61K31/496 , A61K31/506 , C07D491/107 , A61K31/5377 , A61K31/5513 , A61K31/554 , A61K31/437 , A61K31/541
CPC classification number: C07D471/04 , A61K31/437 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/5513 , A61K31/554 , C07D491/107 , C07D519/00
Abstract: A series of imidazo[1,2-a]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Abstract translation: 因此，作为人类TNFα活性的有效调节剂的一系列式（I）的咪唑并[1,2-a]吡啶衍生物因此有益于治疗和/或预防各种人类疾病，包括自身免疫和炎性疾病; 神经和神经退行性疾病; 疼痛和伤害性疾病; 心血管疾病; 代谢紊乱 眼部疾病; 和肿瘤疾病。
-
公开(公告)号：USRE48622E1
公开(公告)日：2021-07-06
申请号：US16517969
申请日：2019-07-22
Inventor： Daniel James Ford , Richard Jeremy Franklin , Anant Ramrao Ghawalkar , Helen Tracey Horsley , Qiuya Huang , James Thomas Reuberson , Bart Vanderhoydonck
IPC: C07D487/04 , A61K31/519 , C07D471/04
Abstract: A series of pyrazolo[3,4-d]pyrimidine derivatives that are substituted at the 4-position by a diaza monocyclic, bridged bicyclic or spirocyclic moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
-
公开(公告)号：US20180362532A1
公开(公告)日：2018-12-20
申请号：US16060486
申请日：2016-12-08
Applicant: UCB Biopharma SPRL , Katholieke Universiteit Leuven
IPC: C07D487/04 , C07D519/00 , A61P29/00 , A61P35/00 , A61P37/06 , A61P33/06 , A61P31/12
CPC classification number: C07D487/04 , A61K31/4985 , A61P29/00 , A61P31/12 , A61P33/06 , A61P35/00 , A61P37/06 , C07D519/00
Abstract: A series of 1,2,6,7,9,9a-hexahydropyrazino[1,2-d][1,2,4]triazin-4-one derivatives, substituted in the 8-position by an optionally substituted fused bicyclic heteroaromatic group, and in the 3-position by a range of functional groups, being selective inhibitors of phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
-
公开(公告)号：US10087180B2
公开(公告)日：2018-10-02
申请号：US15318473
申请日：2015-06-11
Inventor： Daniel James Ford , James Thomas Reuberson
IPC: C07D471/04 , C07D519/00 , A61K31/496
Abstract: A series of pyrazolo[3,4-b]pyridine derivatives that are substituted at the 4-position by a diaza monocyclic, bridged bicyclic or spirocyclic moiety, being selective inhibitors of phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
-
公开(公告)号：US10000497B2
公开(公告)日：2018-06-19
申请号：US15318507
申请日：2015-06-11
Inventor： Helen Tracey Horsley , Qiuya Huang , Judi Charlotte Neuss , James Thomas Reuberson , Bart Vanderhoydonck
IPC: C07D487/04 , C07D403/04 , A61K31/53 , A61K31/495 , A61P33/06 , A61P37/06
CPC classification number: C07D487/04 , A61K31/495 , A61K31/53 , C07D403/04 , Y02A50/411
Abstract: A series of fused bicyclic heteroaromatic derivatives of formula (I), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
-
-
-
-
-
-
-
-
-
Search Results
23
records
(took 0.039 seconds)
